Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

Weekly CTIM-76 results cover nine evaluable ovarian cancer patients; every-three-week efficacy data are expected in Q2 2027.

Rhea-AI Summary

Context Therapeutics (CNTX) reported third-quarter results and CTIM-76 trial follow-up showing a 22% confirmed response rate in platinum-resistant ovarian cancer.

Among nine evaluable patients receiving 140–280 µg weekly, disease control was 56% and median progression-free survival was 5.6 months. Across 27 patients, Grade 3 or higher treatment-emergent adverse events occurred in 81.5%. Escalation to 420 µg every three weeks has begun. Context expects Phase 1b initiation in Q1 2027 and initial every-three-week efficacy data in Q2 2027. CT-202's first Phase 1 patient was dosed in September 2026.

Third-quarter net loss narrowed to $7.6 million from $9.7 million a year earlier. Cash fell to $34.4 million at September 30, 2026, from $66.0 million at December 31, 2025. Context expects funding to last to early Q4 2027.

13 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointCTIM-76 weekly dosing produced 22% confirmed response and 56% disease control in nine evaluable platinum-resistant ovarian cancer patients.
• Moderate pointThird-quarter net loss narrowed to $7.6 million from $9.7 million; loss per share improved to $0.08 from $0.10.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Context expects its $34.4 million cash balance to fund operations to early Q4 2027.
• Minor pointMedian progression-free survival reached 5.6 months in evaluable ovarian cancer patients receiving biologically active weekly doses.
• Minor pointLiver target lesions decreased in all seven assessed lesions across four patients, including two complete disappearances.

8 minor points

• Minor pointCTIM-76 received FDA Fast Track designation for platinum-resistant ovarian cancer after all standard-of-care therapies.
• Minor pointCTIM-76 completed the 280 µg every-three-week toxicity assessment; escalation to 420 µg has begun.
• Minor pointAdditional enrollment of 6 patients at 280 µg every three weeks is underway to characterize that dose.
• Minor point. Forward-looking: it has not happened yet and may not happen.Context expects Phase 1b initiation in Q1 2027 and initial every-three-week efficacy data in Q2 2027.
• Minor pointCT-202's first Phase 1 patient was dosed in September 2026; six Australian sites are active.
• Minor point. Forward-looking: it has not happened yet and may not happen.CT-202's U.S. investigational new drug application remains on track for year-end 2026; initial data are expected in 2H 2027.
• Minor pointThird-quarter research and development expenses declined to $5.7 million from $8.7 million a year earlier.
• Minor pointTotal liabilities decreased to $5,532,662 at September 30, 2026, from $8,020,041 at December 31, 2025.

Negative

• Moderate pointGrade 3 or higher treatment-emergent adverse events occurred in 22 of 27 patients (81.5%).
• Moderate pointCash declined to $34.4 million at September 30, 2026, from $66.0 million at December 31, 2025.
• Moderate pointNine-month net loss widened to $30,862,704 from $23,098,008; loss per share increased to $0.32 from $0.24.
• Moderate pointNine-month research and development expenses increased to $25,261,652 from $20,015,639 a year earlier.
• Moderate pointStockholders' equity declined to $31,005,258 at September 30, 2026, from $60,473,727 at December 31, 2025.

6 minor points

• Minor pointGrade 3 or higher AST and ALT liver-enzyme elevations each affected 4 patients (21.1%) at biologically active doses.
• Minor pointCytokine release syndrome occurred in 5 of 27 patients (18.5%); all events were Grade 1 or 2.
• Minor pointThird-quarter general and administrative expenses rose to $2.2 million from $1.9 million a year earlier.
• Minor pointThird-quarter other income declined to $0.3 million from $0.9 million a year earlier.
• Minor pointNine-month general and administrative expenses increased to $7,011,046 from $5,882,346 a year earlier.
• Minor pointNine-month other income decreased to $1,409,994 from $2,799,977 a year earlier.

News Explained

The added findings detail dose-specific liver-enzyme effects and liver-lesion shrinkage while CTIM-76 dose escalation continues.

The report adds detail on the ongoing CTIM-76 Phase 1: the dose-limiting-toxicity assessment at 280 µg Q3W is complete, escalation to 420 µg Q3W has begun, and six more patients are being enrolled at 280 µg to further characterize that dose.

At biologically active doses, Grade 3 or higher AST and ALT elevations each occurred in four patients (21.1%); the release says liver-enzyme elevations generally occurred early, were asymptomatic, and resolved with continued dosing.

In a separate lesion-level finding, all seven liver target lesions in four patients decreased in size, including two that disappeared completely.

Key Figures

Confirmed ORR: 22% Confirmed DCR: 56% Median PFS: 5.6 months +5 more

Confirmed ORR

22%

PROC patients treated weekly at biologically active doses

Confirmed DCR

56%

PROC patients treated weekly at biologically active doses

Median PFS

5.6 months

Efficacy-evaluable PROC patients treated weekly at biologically active doses

Grade ≥3 treatment-emergent adverse events

81.5% (22 of 27 patients)

Overall CTIM-76-treated patients

Cash and cash equivalents

$34.4 million

As of September 30, 2026

Cash runway

Early Q4 2027

Company expectation for funding operations

Net loss

$7.6 million vs. $9.7 million

Third quarter 2026 vs. third quarter 2025

Research and development expenses

$5.7 million vs. $8.7 million

Third quarter 2026 vs. third quarter 2025

Key Terms

objective response rate, disease control rate, progression-free survival, cytokine release syndrome, +2 more

6 terms

objective response rate medical

"the confirmed objective response rate (“ORR”) was 22%"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

disease control rate medical

"the disease control rate (“DCR”) was 56%"

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

progression-free survival medical

"median progression-free survival (“PFS”) of 5.6 months"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

cytokine release syndrome medical

"Cytokine release syndrome occurred in 5 of 27 patients"

An intense immune overreaction in which the body's defense system releases a large surge of signaling proteins, causing fever, low blood pressure, breathing trouble or organ stress; imagine the immune system's alarm going into overdrive and flooding the body with emergency responders. Investors care because this side effect can slow or block regulatory approval, increase clinical trial costs and liabilities, limit how widely a therapy can be used, and therefore affect a drug's market value and sales potential.

pharmacokinetics medical

"the pharmacokinetic profile supports evaluation of Q3W dosing"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

fast track designation regulatory

"The U.S. FDA has granted Fast Track designation to CTIM-76"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 
56% confirmed DCR, and median PFS of 5.6 months

Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg

Phase 1b initiation expected in Q1 2027 and initial Q3W efficacy data in Q2 2027

Cash and cash equivalents of $34.4 million as of September 30, 2026 expected to fund operations to early Q4 2027

PHILADELPHIA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the third quarter ended September 30, 2026, and reported on recent and upcoming business highlights. The Company also reported longer-term follow-up from weekly (“QW”) dosing and initial safety from every-three-week (“Q3W”) dosing in the ongoing Phase 1 trial of CTIM-76, its Claudin 6 (“CLDN6”) x CD3 TCE.

Longer-term Phase 1 follow-up showed median progression-free survival (“PFS”) of 5.6 months at biologically active weekly doses of 140–280 µg. An emerging association between dose, cytokine and T cell activation, and tumor shrinkage is informing dose selection as the Company optimizes every-three-week dosing and advances toward Phase 1b at a dose of 280 µg or higher. CTIM-76 was generally well tolerated, supporting further Q3W dose escalation from 280 µg to 420 µg. Activity extended to liver metastases, which are typically difficult to treat with immunotherapy:¹ all seven liver target lesions decreased in size, including two that disappeared completely. While preliminary, these efficacy, pharmacodynamic and tolerability findings support continued development of CTIM-76 and further evaluation of its potential as a best-in-class TCE for platinum-resistant ovarian cancer (“PROC”).

“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy,” said Martin Lehr, Chief Executive Officer of Context. “Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness,² providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.³ We view the results to date as an initial benchmark, with Phase 1b providing an opportunity to further define CTIM-76’s clinical potential.”

Recent Pipeline Progress and Upcoming Milestones of Prioritized Clinical Programs:

CTIM-76: CLDN6 x CD3 TCE

Context is evaluating CTIM-76 as a monotherapy in a Phase 1 trial in patients with CLDN6-positive PROC, testicular and endometrial cancers. The U.S. FDA has granted Fast Track designation to CTIM-76 for patients with PROC who have received all standard-of-care therapies.

Patients

• As of October 30, 2026, 27 patients with ovarian (n=20), testicular (n=4) and endometrial (n=3) cancer had received CTIM-76 in dose escalation cohorts, either QW at 22.5 to 560 µg (n=21) or Q3W at 280 µg (n=6).
• Fifteen patients with PROC were treated at biologically active doses, either 140 to 280 µg QW (n=9) or 280 µg Q3W (n=6). These patients had received a median of 6 prior lines of therapy (range, 3–16), and 12 (80%) had received a prior antibody-drug conjugate (“ADC”) therapy, including 5 (33%) who had received two or more ADCs.

Efficacy

• Among efficacy evaluable PROC patients treated QW at biologically active doses (n=9), the confirmed objective response rate (“ORR”) was 22% and the disease control rate (“DCR”) was 56%. Two patients (22%) achieved a confirmed partial response and 3 (33%) had stable disease.
• As of October 30, 2026, median PFS was 5.6 months (95% CI: 1.2–7.4 months) among efficacy-evaluable PROC patients treated QW at biologically active doses.
• Tumor reduction was observed across metastatic sites, including regression of 7 liver lesions in 4 patients (median −58%; range −16% to −100%).
• Patients treated with Q3W dosing continue to be followed; initial Q3W efficacy data are expected in Q2 2027.

Pharmacokinetics and Pharmacodynamics

• Exposure increased approximately dose-proportionally, and the pharmacokinetic profile supports evaluation of Q3W dosing.
• CTIM-76 demonstrated dose-dependent induction of IFN-γ and IL-2, with higher peak cytokine levels and CD69+ CD8 T cell activation observed in patients with tumor reduction, providing clinical pharmacodynamic evidence consistent with the proposed mechanism of target-dependent T cell activation.

Safety

• Cytokine release syndrome occurred in 5 of 27 patients (18.5%); all events were Grade 1 or 2.
• Grade ≥3 treatment-emergent adverse events occurred in 22 of 27 patients (81.5%) overall. The most common were increased gamma-glutamyl transferase (GGT; 37.0%), increased aspartate aminotransferase (AST; 29.6%), increased alanine aminotransferase (ALT; 22.2%), increased lipase (18.5%), and anemia (14.8%).
• Grade ≥3 liver enzyme elevations were dose-related, occurring most frequently at 560 µg QW. At biologically active doses, Grade ≥3 AST and ALT elevations each occurred in 4 patients (21.1%). Hepatic enzyme elevations generally occurred early in treatment, were asymptomatic, and resolved with continued dosing.
  

Dose Escalation and Backfill

• The dose-limiting toxicity (“DLT”) evaluation period at 280 µg Q3W is complete (n=6 patients), and dose escalation to 420 µg Q3W (n=3–6) has begun. An additional 6 patients are being enrolled at 280 µg Q3W to further characterize that dose level.
  

Upcoming Expected Milestones:

• Q1 2027: Initiation of Phase 1b dose expansion
• Q2 2027: Phase 1a initial efficacy data with Q3W dosing in PROC patients

CT-202: Nectin-4 x CD3 TCE

Context is evaluating CT-202 as a monotherapy in a Phase 1 trial in patients with urothelial, colorectal and triple-negative breast cancers.

Recent Progress:

• September 2026: First patient dosed in Phase 1 trial
• Six sites are active in Australia

Upcoming Expected Milestones:

• 2H 2027: Phase 1a initial data
• U.S. investigational new drug application filing on track by year-end 2026

Third Quarter 2026 Financial Results

• Cash and cash equivalents were $34.4 million at September 30, 2026, compared to $66.0 million at December 31, 2025. The Company expects its cash and cash equivalents will be sufficient to fund its operations to early fourth quarter of 2027.
• Research and development expenses were $5.7 million for the third quarter of 2026, compared to $8.7 million for the third quarter of 2025. The decrease was primarily driven by a $3.9 million reduction in CT-202 expenses, reflecting lower contract manufacturing and preclinical expenses. Higher CTIM-76, CT-95 and personnel-related costs partially offset this reduction.
• General and administrative expenses were $2.2 million for the third quarter of 2026, as compared to $1.9 million for the third quarter of 2025. The increase was primarily driven by higher salaries and personnel-related costs, including share-based compensation as compared to the same period in 2025.
• Other income was $0.3 million for the third quarter of 2026, as compared to $0.9 million for the third quarter of 2025, primarily due to lower interest income earned on cash and cash equivalent balances.
• Context reported a net loss of $7.6 million for the third quarter of 2026, as compared to $9.7 million for the third quarter of 2025.
  

References

1 Yu, J., Green, M.D., Li, S. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine 27, 152–164 (2021).

2 Cooper AJ, Sands J. T-cell engagers in small cell lung cancer. Cancer. 2026 Sep 15;132(18):e70600.

3 Sands J, et al. Tarlatamab plus durvalumab versus durvalumab alone in extensive-stage small-cell lung cancer: a phase 3 trial. New England Journal of Medicine. 2026;385(18):1623-1634.

About Context Therapeutics®

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia, PA. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, prospects, and plans and objectives of management, are forward-looking statements. These statements may be identified by words such as “may,” “will,” “expect,” “believe,” “could,” “estimate,” “potential,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions.

Forward-looking statements in this press release include, without limitation, statements regarding: (i) plans related to the Company’s research and development activities, and the expected timing and potential results thereof, including trial design and patient enrollment criteria, dose selection and escalation, Q3W dose optimization and the initiation of a Phase 1b dose expansion trial of CTIM-76; (ii) the potential for CTIM-76 to demonstrate improved efficacy or tolerability in less heavily pretreated patients and in Q3W dosing; (iii) the expected timing of clinical data for CTIM-76 and CT-202; (iv) the expected timing of regulatory filings; (v) the Company’s expectation regarding the sufficiency of its cash and cash equivalents; and (vi) other non-historical statements.

These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and the Company cannot assure that its plans, intentions, expectations, or strategies will be achieved. These risks and uncertainties include, without limitation: (i) uncertainties regarding the Company’s expectations, projections, and estimates of future costs and expenses, capital requirements, the availability of additional financing and the Company’s capital requirements, including the Company’s ability to continue as a going concern; (ii) the timing, progress, and results of the Company’s discovery, preclinical and clinical development activities; (iii) clinical trial site activation and enrollment; (iv) unexpected safety or efficacy data observed during preclinical studies or clinical trials; (v) the risk that results from nonclinical or clinical studies may not be predictive of future results, and that interim data are subject to further analysis and may change as more patient data become available; (vi) uncertainties related to the regulatory approval process; (vii) the Company’s reliance on third parties; (viii) macroeconomic conditions; and (ix) whether the Company has sufficient funding to meet future operating expenses and capital expenditure requirements.

Additional factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and future reports.

Context Therapeutics Inc.
Condensed Statements of Operations
(Unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Operating Expenses
Research and development		$	5,716,786			$	8,722,104			$	25,261,652			$	20,015,639
General and administrative			2,244,622				1,888,376				7,011,046				5,882,346
Loss from operations			(7,961,408	)			(10,610,480	)			(32,272,698	)			(25,897,985	)
Other income			337,702				917,243				1,409,994				2,799,977
Net loss		$	(7,623,706	)		$	(9,693,237	)		$	(30,862,704	)		$	(23,098,008	)
Net loss per common share, basic and diluted			($0.08	)			($0.10	)			($0.32	)			($0.24	)
Weighted average shares outstanding, basic and diluted			95,183,718				95,185,187				95,183,718				95,186,346
Context Therapeutics Inc.
Condensed Balance Sheets Data
(Unaudited)
		September 30,				December 31,
			2026				2025
Cash and cash equivalents		$	34,410,919			$	65,995,228
Other assets			2,127,001				2,498,540
Total assets		$	36,537,920			$	68,493,768
Total liabilities		$	5,532,662			$	8,020,041
Total stockholders' equity			31,005,258				60,473,727
Total liabilities and stockholders' equity		$	36,537,920			$	68,493,768

Investor Relations Contact:

Jennifer Minai-Azary, Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Context Therapeutics' CTIM-76 trial show in platinum-resistant ovarian cancer?

Among nine efficacy-evaluable patients receiving 140–280 µg weekly, CTIM-76 achieved a 22% confirmed objective response rate and 56% disease control rate. Two patients had confirmed partial responses and three had stable disease. Median progression-free survival was 5.6 months, with a 95% confidence interval of 1.2–7.4 months, as of October 30, 2026.

How long does Context Therapeutics expect its cash to last?

Context expects its $34.4 million in cash and cash equivalents at September 30, 2026, to fund operations to early fourth quarter 2027. Cash and cash equivalents were $66.0 million at December 31, 2025.

Which patients does Context Therapeutics plan to enroll in CTIM-76 Phase 1b?

Context plans to evaluate CTIM-76 in patients with no more than five prior lines of therapy in Phase 1b. The company considers this less heavily pretreated population a way to evaluate whether lower tumor burden and better T cell fitness, together with every-three-week dosing, can improve clinical benefit and tolerability.

What liver safety findings did Context Therapeutics report for CTIM-76?

Grade 3 or higher liver-enzyme elevations were dose-related and occurred most frequently at 560 µg weekly. At biologically active doses, severe AST and ALT elevations each occurred in four patients (21.1%). Hepatic enzyme elevations generally occurred early, were asymptomatic and resolved with continued dosing.